Journal of Managed Care & Specialty Pharmacy

Papers
(The H4-Index of Journal of Managed Care & Specialty Pharmacy is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Correction109
What is needed to sustain comprehensive medication management? One health plan’s perspectives58
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data45
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review23
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance20
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness20
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder20
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues18
The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US 18
PIVOT: Pharmacist Interventions for Value and Outcome Transformation in Specialty Pharmacy17
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis15
Compliance with the Veterans Health Administration’s Pharmacy Benefit Management guidance for duration of clopidogrel following peripheral vascular interventions: a retrospective cohort study15
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy14
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia14
0.25853204727173